一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Gynecologic oncology >>article
Gynecologic oncology

Gynecologic oncology

IF: 4.1
Download PDF

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma

Published:5 April 2024 DOI: 10.1016/j.ygyno.2024.03.029
Robert L. Hollis , Richard Elliott , John C. Dawson , Narthana Ilenkovan , Rosie M. Matthews , Lorna J. Stillie , Ailsa J. Oswald , Hannah Kim , Marta Llaurado Fernandez , Michael Churchman , Joanna M. Porter , Patricia Roxburgh , Asier Unciti-Broceta , David M. Gershenson , C. Simon Herrington , Mark S. Carey , Neil O. Carragher , Charlie Gourley

Abstract

Background

Low grade serous ovarian carcinoma (LGSOC) is a distinct histotype of ovarian cancer characterised high levels of intrinsic chemoresistance, highlighting the urgent need for new treatments. High throughput screening in clinically-informative cell-based models represents an attractive strategy for identifying candidate treatment options for prioritisation in clinical studies.

Methods

We performed a high throughput drug screen of 1610 agents across a panel of 6 LGSOC cell lines (3 RAS/RAF-mutant, 3 RAS/RAF-wildtype) to identify novel candidate therapeutic approaches. Validation comprised dose-response analysis across 9 LGSOC models and 5 high grade serous comparator lines.

Results

16 hits of 1610 screened compounds were prioritised for validation based on >50% reduction in nuclei counts in over half of screened cell lines at 1000?nM concentration. 11 compounds passed validation, and the four agents of greatest interest (dasatinib, tyrosine kinase inhibitor; disulfiram, aldehyde dehydrogenase inhibitor; carfilzomib, proteasome inhibitor; romidepsin, histone deacetylase inhibitor) underwent synergy profiling with the recently approved MEK inhibitor trametinib. Disulfiram demonstrated excellent selectivity for LGSOC versus high grade serous ovarian carcinoma comparator lines (P?=?0.003 for IC50 comparison), while the tyrosine kinase inhibitor dasatinib demonstrated favourable synergy with trametinib across multiple LGSOC models (maximum zero interaction potency synergy score 46.9). The novel, highly selective Src family kinase (SFK) inhibitor NXP900 demonstrated a similar trametinib synergy profile to dasatinib, suggesting that SFK inhibition is the likely driver of synergy.

Conclusion

Dasatinib and other SFK inhibitors represent novel candidate treatments for LGSOC and demonstrate synergy with trametinib. Disulfiram represents an additional treatment strategy worthy of investigation.

Similar articles

湘西| 定南县| 平陆县| 富宁县| 南岸区| 印江| 阳春市| 闸北区| 大田县| 中西区| 于都县| 阜宁县| 专栏| 蛟河市| 昌邑市| 通榆县| 潞城市| 罗平县| 彩票| 东源县| 金华市| 怀安县| 通城县| 和静县| 巩义市| 沂源县| 松滋市| 黑龙江省| 宿州市| 庆云县| 建湖县| 白银市| 普兰店市| 大同市| 合江县| 原平市| 长顺县| 昌吉市| 虹口区| 连州市| 白水县|